

# Peripheral arterial disease

---


- **Asif Serajian DO FACC**
- **No disclosures relevant to this talk**

# Demographics


---

- **Over age 50**
- **1/3 diabetic**
- **50% have CAD**

# Progression of Intermittent Claudication




# Decline in Survival Associated With Severity of PAD



ABI = ankle-brachial index, PAD = peripheral arterial disease.  
McKenna M et al. *Atherosclerosis*. 1991;87:119-128.


# Peripheral Arterial Disease and Relative Risk of Death



# Long-term Risk of MI and Stroke

PAD  
 Post-MI  
 Post-Stroke


## Vascular Disease: A Generalized and Progressive Process



1. Adult Treatment Panel II. *Circulation*.
2. Kannel WB. *J Cardiovasc Risk*.
3. Willetdink JJ, Easton JD. *Arch Intern Med*.
4. Criqui MH et al. *N Engl J Med*. 1992;326:691-699.

Adapted from Stary HC et al. *Circulation*. 1995;92:1355-1374 and Fuster V. *Vasc Med*. 1998;3:231-239.

© 2001 American Heart Association. All rights reserved.



**PRIMARY SITES OF INVOLVEMENT**  
**Femoral & Popliteal arteries: 80-90%**

**Tibial & Peroneal arteries: 40-50%**

**Aorta & Iliac arteries: 30%**

# DIAGNOSIS

---

- History taking
- Careful examination of leg
- Pulse evaluation
- Ankle-brachial index (ABI):  
SBP in ankle (dorsalis pedis and posterior tibial arteries)

---

SBP in upper arm (brachial artery)

*Am J Cardiol 2001; 87 (suppl): 3D-13D*

*NEJM 2001; 344: 1608-1621*



# Ankle-Brachial Index Values and Clinical Classification

---

Clinical Presentation	Ankle-Brachial Index
<b>Normal</b>	<b><math>&gt; 0.90</math></b>
<b>Claudication</b>	<b>0.50-0.90</b>
<b>Rest pain</b>	<b>0.21-0.49</b>
<b>Tissue loss</b>	<b><math>&lt; 0.20</math></b>

---

Values  $>1.25$  falsely elevated; commonly seen in diabetics

*Am J Cardiol 2001; 87 (suppl): 3D-13D*  
*NEJM 2001; 344: 1608-1621*

# Other Noninvasive Diagnostic Tests

---

- Segmental blood pressure recording
- Segmental pulse volume recording
- Exercise stress testing
- Reactive hyperemia
- CW Doppler and duplex ultrasound

# WHY IS IT NECESSARY TO TREAT INTERMITTENT CLAUDICATION ?

---

- Symptoms worsen in 25% of patients
- Approximately 5% will require amputation within 5 years
- Around 5-10% have critical limb ischemia; risk of limb loss
- Increased risk of mortality, primarily for cardiovascular causes

*Am J Cardiol 2001; 87 (suppl): 3D-13D*

# MODIFICATION OF RISK FACTORS

---

- Smoking cessation
- Diabetes control (FBG 80-120 mg/dl, PPG  $\leq$  180 mg/dl, HbA<sub>1c</sub>  $<$  7%)
- Dyslipidemia management (LDL  $<$  100 mg/dl, TG  $<$  150 mg/dl): Statins (RR 38%; 4S)
- Hypertension control (BP  $<$  130/85 mmHg)
- Ramipril [RR 28%; HOPE (n=4051)]

*Am J Cardiol* 2001; 87 (suppl): 3D-13D

*NEJM* 2001; 344: 1608-21

*Am J Med* 2002; 112: 49-57

# ANTIPLATELET THERAPY

---

- Aspirin
- Clopidogrel (CAPRIE Study)

No studies have shown that aspirin or clopidogrel improves claudication symptoms

# FDA approved drugs for IC

---

- **Pentoxifylline – 1984**
- **CILOSTAZOL - 1999**

# PENTOXIFYLLINE NOT RECOMMENDED FOR INTERMITTENT CLAUDICATION

- Inconsistent and modest benefit; non-significant increase in walking ability
- Not more effective than placebo in increasing walking ability or functional status
- Most trials small and not properly designed
- Study sample size and pentoxifylline response inversely correlated

**“Data are insufficient to support its widespread use”**

**(Meta-analysis of pentoxifylline trials)**

*NEJM 2001; 344: 1608-1621*

*Am J Cardiol 2001; 87 (suppl): 19D-27D*

# Pharmacology of Cilostazol

---

- 9 genes identified for Phosphodiesterases, PDE I-IX
- cAMP is degraded by PDE-III present in
  - Vascular smooth muscle
  - Platelets
  - Cardiomyocytes
  - Endothelial cells
- cAMP mediates platelet inhibitory, vasodilatory and vascular antiproliferative responses in vivo



# CILOSTAZOL EXERTS SIGNIFICANT ANTIPLATELET EFFECTS

---


- Inhibits platelet aggregation induced by ADP, collagen, adrenaline, arachidonic acid and thrombin
- More potent in suppressing platelet aggregation than aspirin or ticlopidine

*Ann Pharmacother* 2001; 35: 48-56

*Drugs & Aging* 1999; 14: 63-71

*Arzneim Forschung* 1987; 37: 563-566

# IMPROVES ANKLE-BRACHIAL INDEX



N=239; 16 wks  
P value betn gps <0.0125

*J Vasc Surg* 1998; 27: 267-275

# CILOSTAZOL AND HAND ISCHEMIA

---

Three cases of digital ischemia successfully treated with cilostazol

Patient 1: Chronic, post-traumatic, cold, painful right fourth and fifth fingers. After 8 weeks of cilostazol therapy, fingers were warm and displayed normal perfusion



Patient 2: Painful index finger ulceration. Within 4 weeks of cilostazol therapy, digital ulcers and pain resolved

Patient 3: Traumatic right fifth digital arterial thrombosis. Within 4 weeks of cilostazol therapy, pain and cyanosis had resolved


Primary treatment




A year later



**Early**



**After 2 years**




# Tiboperoneal vessels usually involved


---



# Pulse volume recording



# Arterial duplex





# TASC Classification/Recommendations SFA/Popliteal



Type A

Type B

→ Endovascular Tx



Type C



Type D

→ Surgical Tx

Lesion type	Description
A	Single stenosis $\leq 10$ cm in length Single occlusion $\leq 5$ cm in length
B	Multiple lesions (stenoses or occlusions), each $\leq 5$ cm Single stenosis or occlusion $\leq 15$ cm not involving the infrageniculate popliteal artery Single or multiple lesions in the absence of continuous tibial vessels to improve inflow for a distal bypass Heavily calcified occlusion $\leq 5$ cm in length Single popliteal stenosis
C	Multiple stenoses or occlusions totaling $> 15$ cm with or without heavy calcification Recurrent stenoses or occlusions that need treatment after two endovascular interventions
D	Chronic total occlusions of CFA or SFA ( $> 20$ cm, involving the popliteal artery) Chronic total occlusion of popliteal artery and proximal trifurcation vessels

# Vascular Surgical Procedures for Outflow Improvement

<b>Outflow Procedure</b>	<b>Operative Mortality (%)</b>	<b>Expected Patency Rate (%)</b>
Fem-AK popliteal vein	1.3 to 6.3	66 (5 years)
Fem-AK popliteal prosthetic	1.3 to 6.3	50 (5 years)
Fem-BK popliteal vein	1.3 to 6.3	66 (5 years)
Fem-BK popliteal prosthetic	1.3 to 6.3	33 (5 years)



# Assessment of touch pressure

---

- 10 gram monofilament
- Assesses loss of protective sensation
- Failure defined by inability to sense 4/10 locations per plantar aspect
- Insensate patients have 7x risk of ulcer!!



	Fontaine			Rutherford
Stage	Clinical	Grade	Category	Clinical
I	Asymptomatic	0	0	Asymptomatic
IIa	Mild Claudication	0	1	Mild Claudication
IIb	Moderate/Severe	I	2	Moderate
III	Rest Pain	II,III	3	Severe
IV	Ulcer/Gangrene	III	4	Rest Pain/Minor Tissue Loss
			5	Minor Tissue Loss
			6	Major Tissue Loss


# ABI Measurement

Right arm  
pressure

Left arm  
pressure

Pressure:  
PT  
DP

Pressure:  
PT  
DP




<b>ABI Result</b>	<b>Clinical Interpretation</b>	<b>Comments</b>
<b>&gt;1.3</b>	<b>Non-compressible</b>	<b>Results not useful</b>
<b>1.0-1.3</b>	<b>Partially Non-compressible</b>	<b>Need to Correlate with history</b>
<b>0.97-1.0</b>	<b>Normal</b>	
<b>0.8-0.96</b>	<b>Mild Ischemia</b>	<b>Walk 2 blocks pain free</b>
<b>0.4-0.79</b>	<b>Moderate to Severe</b>	<b>Pain at &lt; 2 blocks</b>
<b>&lt;0.39</b>	<b>Severe Ischemia</b>	<b>Potential limb loss</b>

# Segmental pressure test

Location of Pressure	Normal Values
Ankle Pressure	> Brachial Pressure
Ankle Pressure Index	1.0-1.2, Abnormal is <0.95
Ankle Pressure p Exercise	<20% decrease of Baseline
Proximal thigh pressure	30-40mmHg > brachial
Segmental Pressures	< 20mmHg difference in levels
Toe Pressure	>60% of brachial pressure
Toe Index	Normal >0.60, Ischemic rest pain <0.15



# Iliac stenosis



# Abdominal aortic aneurysm

---

- 98% infra-renal
- Defined as AP diameter  $\geq 3$
- Risk factors are smoking, hypertension and family history
- Exam may have bruit, they may present with back pain
- Monitoring  $< 4$  cm US q 2 -3 years, 4- 5.4 monitor q 6 to 12 months
- Surgery for  $> 5.5$  or size  $> 0.5$  cm/ 6 mo

# Thoracic aortic aneurysm

---

- Marfan's syndrome
- Bicuspid aortic valve
- Turner's syndrome
- Loey's-Dietz Syndrome

# Acute arterial occlusion

---

- **Cardiac origin 80-90%**
- **Atrial fibrillation = 75%**
- **left ventricular thrombus**
- **Endocarditis**
- **La mixoma**
- **Paradoxical**
- **Plaque ulceration**

# Arterial occlusion

---

- Pain
- Pallor
- Polar
- Pulseless
- Parenthesis
- Paralysis

# DDx

---

- **Phlegmasia cerulean dolens**
- **Aortic dissection**
- **Low cardiac output state**

# **Buerger's disease: Thromboangiitis Obliterans**

---

- **Inflammatory occlusive disease of small and medium sized peripheral arteries and veins**
- **Young male (90% males)**
- **Age of onset = < 50 years and at times < 30 years**
- **Risk factor is smoking**

- 
- **Numbness/parathesias**
  - **Writer's cramp**
  - **Ulceration**
  - **Claudication**
  - **Thrombophlebitis (migrating)**
  - **May involve distal digits**